BioSpace News Archive

The global arthritis therapeutics market is estimated to experience dynamic growth over forecast tenure, from 2019 to 2027.

ViaDerma, Inc., is pleased to announce they have expanded their current licensing agreement with a home health wound care network.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the company will be participating in the LD Micro Invitational XI Conference, being held virtually from June 8-10, 2021.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will present at the following upcoming virtual investor conferences

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group, provided an update regarding the clinical development of pegunigalsidase alfa for the proposed treatment of Fabry disease.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021.

Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboarding European CTS Customers

Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022

Skylight Health has been selected as a clinical site to enroll patients for a clinical research trial investigating ADG20, a broadly neutralizing monoclonal antibody, for use in the prevention of COVID-19